Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland

International Journal of COPD

Volumn 8, Issue , 2013, Pages 79-87

  Samyshkin, Yevgeniy ^a   Schlunegger, Michael ^b   Haefliger, Susan ^b   Ledderhose, Sabine ^b   Radford, Matthew ^a  

^a IQVIA   (United States)

^b Takeda Pharmaceuticals International GmbH   (Switzerland)

Author keywords

COPD; Cost effectiveness; Economic; Exacerbations; Modeling; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; ROFLUMILAST;

ADD ON THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HIDDEN MARKOV MODEL; HOSPITALIZATION COST; HUMAN; LIFE EXPECTANCY; MORTALITY; QUALITY ADJUSTED LIFE YEAR; STANDARDIZED MORTALITY RATIO; SWITZERLAND; UNSPECIFIED SIDE EFFECT;

COPD; COST-EFFECTIVENESS; ECONOMIC; EXACERBATIONS; MODELING; TREATMENT;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AMINOPYRIDINES; BENZAMIDES; COHORT STUDIES; COST-BENEFIT ANALYSIS; CYCLOPROPANES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; LIFE EXPECTANCY; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMETRIC; MUSCARINIC ANTAGONISTS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; SWITZERLAND;

EID: 84873396034     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S37486     Document Type: Article

References (21)

1. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J. 2007;30(5):993-1013.
2. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741-750.
3. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease Revised 2011. Global Initiative for Chronic Obstructive Lung Disease, Inc; 2011. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf. Accessed August 20, 2012.
4. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61(3):250-258.
5. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685-694.
6. Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with longacting β2-agonists for COPD: influence of exacerbation history. Eur Respir J. 2011;38(3):553-560.
7. Bundesamt für Gesundheit. Bulletin 6/12. Bern: Bundesamt für Gesundheit BAG; 2012. Available from: http://www.bag.admin.ch/dokumentation/publikationen/01435/11505/12789/index.html?lang=de&sort=ta&superflex=0_0&filter_dms_thema=10&filter_dms_fix=327&filter_dms_jahre=. Accessed November 11, 2012.
8. Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis. 2012;7:183-199.
9. Royal College of Physicians. Report of the National Chronic Obstructive Pulmonary Disease Audit 2008: Clinical Audit of COPD Exacerbations Admitted to Acute NHS Units Across the UK 2008. London: Royal College of Physicians; 2008. Available from: http://www.rcplondon.ac.uk/sites/default/files/report-of-the-national-copd-audit-2008-clinical-audit-of-copd-exacerbations-admitted-to-acute-nhs-units-across-the-uk.pdf. Accessed August 15, 2012.
10. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981;123(6):659-664.
11. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000;161(2 Pt 1):381-390.
12. Mills EJ, Druyts E, Ghement I, Puhan MA. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol. 2011;3:107-129.
13. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619-637.
14. Rutten-van Mölken MP, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics. 2009;27(6):465-477.
15. Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC. Trastuzumab beyond progression: a cost-utility analysis. Ann Oncol. 2010;21(11):2161-2168.
16. Matter-Walstra K, Joerger M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health. 2012;15(1): 65-71.
17. WHO. WHO-CHOICE [webpage on the Internet]. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Geneva: World Health Organization; 2012. Available from: http://www.who.int/choice/en. Accessed July 2, 2012.
18. Schramm W, Haake D, Brandt A. Die Wirtschaftlichkeit von Tiotropium bei chronisch obstruktiver Lungenerkrankung [Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease]. Praxis (Bern 1994). 2005;94(46):1803-1810. German.
19. Oostenbrink JB, Rutten-van Mölken MP, Monz BU, FitzGerald JM. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health. 2005;8(1):32-46.
20. compendium.ch [webpage on the Internet]. medicines Compendium of Switzerland®. Basel; Documed Ltd; 2012. Available from: http://www.kompendium.ch. Accessed July 2, 2012. German, French, English.
21. TARMED Suisse [homepage on the Internet]. Bern: TARMED Suisse; 2011. Available from: http://www.tarmedsuisse.ch/. Accessed July 2, 2012.